AAV-mediated expression of a SARS-CoV-2 neutralizing antibody in monocyte-derived dendritic cells and human airway epithelial cells.
AAV6.2FF is qualified as a promising platform for localized mAb expression in the human respiratory tract for adeno-associated virus (AAV) vectors to enable full mAb expression in human respiratory cell subsets.